Agnusdei D - Search Results

1

A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.

Agnusdei D, Crepaldi G, Isaia G, Mazzuoli G, Ortolani S, Passeri M, Bufalino L, Gennari C. Agnusdei D, et al. Calcif Tissue Int. 1997 Aug;61(2):142-7. doi: 10.1007/s002239900312. Calcif Tissue Int. 1997. PMID: 9236262 Clinical Trial.

2

Short-term treatment of Paget's disease of bone with ipriflavone.

Agnusdei D, Camporeale A, Gonnelli S, Gennari C, Baroni MC, Passeri M. Agnusdei D, et al. Bone Miner. 1992 Oct;19 Suppl 1:S35-42. doi: 10.1016/0169-6009(92)90864-a. Bone Miner. 1992. PMID: 1422319 Clinical Trial.

3

Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.

Agnusdei D, Adami S, Cervetti R, Crepaldi G, Di Munno O, Fantasia L, Isaia GC, Letizia G, Ortolani S, Passeri M, et al. Agnusdei D, et al. Bone Miner. 1992 Oct;19 Suppl 1:S43-8. doi: 10.1016/0169-6009(92)90865-b. Bone Miner. 1992. PMID: 1422320 Clinical Trial.

4

An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.

Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R. Gennari C, et al. Among authors: agnusdei d. Calcif Tissue Int. 1992 Apr;50(4):381-3. doi: 10.1007/BF00301638. Calcif Tissue Int. 1992. PMID: 1571851 Clinical Trial.

5

Use of calcitonin in the treatment of bone pain associated with osteoporosis.

Gennari C, Agnusdei D, Camporeale A. Gennari C, et al. Among authors: agnusdei d. Calcif Tissue Int. 1991;49 Suppl 2:S9-13. doi: 10.1007/BF02561370. Calcif Tissue Int. 1991. PMID: 1933618 Review.

6

Calcitonin, estrogens and the bone.

Gennari C, Agnusdei D. Gennari C, et al. Among authors: agnusdei d. J Steroid Biochem Mol Biol. 1990 Nov 20;37(3):451-5. doi: 10.1016/0960-0760(90)90497-9. J Steroid Biochem Mol Biol. 1990. PMID: 2257249 Clinical Trial.

7

Calcitonins and osteoporosis.

Gennari C, Agnusdei D. Gennari C, et al. Among authors: agnusdei d. Br J Clin Pract. 1994 Jul-Aug;48(4):196-200. Br J Clin Pract. 1994. PMID: 7917799 Review.

8

Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.

Agnusdei D, Gennari C, Bufalino L. Agnusdei D, et al. Osteoporos Int. 1995;5(6):462-6. doi: 10.1007/BF01626609. Osteoporos Int. 1995. PMID: 8695969 Clinical Trial.

9

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.

Gennari C, Adami S, Agnusdei D, Bufalíno L, Cervetti R, Crepaldi G, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Mazzuoli GF, Ortolani S, Passeri M, Serni U, Vecchiet L. Gennari C, et al. Among authors: agnusdei d. Calcif Tissue Int. 1997;61 Suppl 1:S19-22. doi: 10.1007/s002239900380. Calcif Tissue Int. 1997. PMID: 9263612 Clinical Trial.

10

Efficacy of ipriflavone in established osteoporosis and long-term safety.

Agnusdei D, Bufalino L. Agnusdei D, et al. Calcif Tissue Int. 1997;61 Suppl 1:S23-7. doi: 10.1007/s002239900381. Calcif Tissue Int. 1997. PMID: 9263613 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters